Acadia starts Phase 2 trial of pimavanserin in ADP

• Acadia Pharmaceuticals (NASDAQ:ACAD) initiates a Phase 2 feasibility trial of pimavanserin in Alzheimer's disease psychosis (for which there are no treatments approved in the U.S.).
• The company says Phase 3 results in Parkinson's disease psychosis (that's -020) suggest the drug "may offer the potential for an important new therapeutic advance" in ADP. (PR)
• In a recent article, SA contributor Jason Napodano said "several pieces of evidence point to a successful outcome" in ADP. He calls the drug "the next blockbuster for psychosis."